Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Lipocine (LPCN) over the last 13 years, with Q3 2025 value amounting to $63888.0.

  • Lipocine's Change in Accured Expenses rose 863.83% to $63888.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$542618.0, marking a year-over-year decrease of 45705.13%. This contributed to the annual value of -$297246.0 for FY2024, which is 31119.02% down from last year.
  • Lipocine's Change in Accured Expenses amounted to $63888.0 in Q3 2025, which was up 863.83% from $66369.0 recorded in Q2 2025.
  • Lipocine's 5-year Change in Accured Expenses high stood at $472012.0 for Q2 2024, and its period low was -$554554.0 during Q4 2021.
  • Its 5-year average for Change in Accured Expenses is -$47553.2, with a median of $55888.0 in 2023.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first soared by 64579.29% in 2022, then plummeted by 91774.44% in 2024.
  • Quarter analysis of 5 years shows Lipocine's Change in Accured Expenses stood at -$554554.0 in 2021, then surged by 135.5% to $196888.0 in 2022, then tumbled by 60.3% to $78173.0 in 2023, then tumbled by 574.65% to -$371045.0 in 2024, then skyrocketed by 117.22% to $63888.0 in 2025.
  • Its Change in Accured Expenses was $63888.0 in Q3 2025, compared to $66369.0 in Q2 2025 and -$301830.0 in Q1 2025.